Bavarian Nordic wins its biggest ever contract for smallpox vaccines  

Copenhagen based Bavarian Nordic to mass supply smallpox vaccines to an un-named government

The Copenhagen based biotech company Bavarian Nordic has signed an agreement with an un-named government for the supply of smallpox vaccine of the type Elstree-BN. The order is Bavarian Nordic’s largest ever and the company is now already sure of reaching a turnover of DKK 500 million (USD 72 million) this year and pre-tax profits of DKK 250 million (USD 36 million), the figures accounting for the bulk of its 2003 sales and profits targets announced in December 2002.


Bavarian Nordic makes two different types of smallpox vaccine, Elstree-BN and MVA-BN, the first being an older second generation type which can be dangerous to individuals with compromised immune defences, while the latter is a newly developed third generation vaccine which is completely safe even for those with weaker immune systems. Bavarian Nordic has great expectations of gaining a good chunk of the world market with MVA-BN. The company envisions that it could generate a total turnover of DKK 5 billion (725 million) by around 2010.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×